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Zinc is a micronutrient, which is essential for human
health, playing role as a cofactor of enzymes such as
dehydrogenases, peptidases and component of zinc finger
domains. In organism zinc is involved in metabolic path-
ways, immune processes, maintaining ion balance
between other elements. Recently, it has been reported
that zinc may play role in chemoprevention, and its level
may be associated with cancer risk.
Aim of the study
The aim of this study was to analyze possible association
between serum zinc level and breast cancer risk in
BRCA1 mutation carriers and noncarriers.
Materials and methods
The studies have been performed on 3 independent
groups: (1) 119 unselected breast cancer patients matched
1:1 with 119 unaffected controls (carriers of BRCA1 muta-
tion have been excluded), (2) 99 breast cancer cases
(serum collected at the moment of diagnosis, before treat-
ment) and 198 matched 1:2 unaffected controls, (3):27
breast cancer cases (serum collected 1-2 years before diag-
nosis) and 53 controls matched 1:2. All individuals in
groups (2) and (3) were carriers of BRCA1 mutation.
Zinc level in serum was measured by inductively
coupled plasma mass spectrometry (ICP-MS) using Elan
DRC-e ICP-Mass Spectrometer, Perkin Elmer.
Results
In the group of unselected breast cancer patients, indivi-
duals with zinc level 759,64-985,24 μg/L had a lower
risk of breast cancer than those with zinc level
107,18–759,64 μg/L. Observation was statistically insig-
nificant (OR=0,712; p=0,34).
In group of BRCA1 carriers, in which serum was col-
lected at the moment of diagnosis, individuals with zinc
level 692,48 – 756,01 μg/L had significantly lower risk of
breast cancer than those with zinc level 218, 89 – 692,
48 μg/L (OR = 0,446, p = 0,02709).
In the group of BRCA1 carriers, in which serum was
collected 1-2 years before diagnosis, individuals with
zinc level >831,35) had significantly lower risk of breast
cancer (OR = 0,222; p = 0,0063).
Conclusions
We observed that serum zinc level is associated with
breast cancer risk in BRCA1 carriers and noncarriers.
Analysis of serum zinc concentration revealed tendency to
increased risk of breast cancer for unselected breast can-
cers and BRCA1 carriers with zinc level <750±50 μg/L.
Probably high zinc level reduces cancer risk especially in
BRCA1 carriers, but these results should be confirmed in
larger cohorts.
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